中国肺癌杂志2017，Vol.20Issue(2)：124-129,6.DOI:10.3779/j.issn.1009-3419.2017.02.07
早期非小细胞肺癌ALK阳性患者的临床研究进展
Clinical Advanced in Early-stage ALK-positive Non-small Cell Lung Cancer Patients
摘要
Abstract
Lung cancer is the leading cause of cancer death in China. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases, with the majority of the cases diagnosed at the advanced stage. Molecular targeted therapy is be-coming the focus attention for advanced NSCLC. Echinoderm microtubule-associated protein-like 4 gene and the anaplastic lymphoma kinase gene (EML4-ALK) is among the most common molecular targets of NSCLC; its specific small-molecule tyrosine kinase inhibitors (TKIs) are approved for use in advanced NSCLC cases of ALK-positive. However, the influence of EML4-ALK fusion gene on the outcome of early-stage NSCLC cases and the necessity of application of TKIs for early-stage ALK-positive NSCLC patients are still uncertain. In this paper, we summarized the progression of testing methods for ALK-positive NSCLC patients as well as clinicopathological implication, outcome, and necessity of application of TKIs for early-stage ALK-positive NSCLC patients.关键词
肺肿瘤/ALK/检测/临床病理特征/预后Key words
Lung neoplasms/ALK/Testing/Clinicopathological implication/Outcome引用本文复制引用
高琼琼,蒋湘俐,黄纯..早期非小细胞肺癌ALK阳性患者的临床研究进展[J].中国肺癌杂志,2017,20(2):124-129,6.基金项目
本文受国家自然科学基金面上项目(No.81372467)资助 This paper was supported by the grant from the General Programs of the National Natural Science Foundation of China (to Chun HUANG)(No.81372467). （No.81372467）
